Pharmaceutical News

RSS

Decision Resources: 52% of surveyed cardiologists identify furosemide as efficacious acute heart failure therapy

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the highest proportion of surveyed cardiologists identify furosemide as the most efficacious agent for the treatment of acute heart failure when compared to other available therapies.

1 Mar 2011

Excella achieves SafeBridge Potent Compound Safety Certification

SAFEBRIDGE® CONSULTANTS, INC., headquartered in Mountain View, California, has announced that Excella GmbH in Feucht, Germany has met the criteria established under the SafeBridge program for "Potent Compound Safety Certification" and has been deemed competent and proficient in the safe handling of potent active pharmaceutical ingredients ("APIs") and potent drug products.

1 Mar 2011

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announces that the Company's commercialization partner, Meda AB, has launched Medivir's unique cold sore treatment Xerese in the United States.

1 Mar 2011

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Patients in Sweden living with peripheral neuropathic pain are set to gain access to a new treatment option which can provide pain relief for up to three months following a single 30- or 60-minute application. The new treatment patch uses capsaicin - the substance found in chilli peppers which gives them their 'heat' - to change the function of pain sensing nerves in the area of skin affected.

1 Mar 2011

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that the Company has obtained an exclusive license from Massachusetts General Hospital for intellectual property related to the regulation of miR-33 for the treatment of cardiovascular disorders.

1 Mar 2011

Novavax announces agreement to license VLP vaccine technology to LGLS

Novavax, Inc. announced today an agreement to license its proprietary, recombinant virus-like-particle vaccine technology to LG Life Sciences, Ltd.

1 Mar 2011

HP announces innovative drug research application for its inkjet technology

HP today announced an innovative drug research application for its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.

1 Mar 2011

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals for the development of an active vaccination programme against Alzheimer's disease.

1 Mar 2011

Nile plans to develop novel therapeutics for ADHF

Nile Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, announced plans to pursue a new indication in the field of heart failure.

1 Mar 2011

HHS awards two contracts to accelerate flu vaccine availability

U.S. Department of Health and Human Services awarded two contracts today to help make vaccine available more quickly for seasonal flu outbreaks and pandemics. The contracts for advanced development of new types of vaccine and new ways to make flu vaccine known as next-generation recombinant influenza vaccine total $215 million.

28 Feb 2011

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and CellSeed Inc., a Japanese biotechnology firm, have entered into a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine, "Cell Sheet Engineering," LA BioMed President and CEO David I. Meyer, PhD, announced today.

28 Feb 2011

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

AFFiRiS AG announced today significant progress in their collaboration with GlaxoSmithKline Biologicals (GSK) for the development of an active vaccination programme against Alzheimer´s disease. While the lead vaccine candidate AD02 is currently in phase II clinical testing, two additional preclinical programmes have been completed successfully. The second programme was related to alternative vaccine candidates generated by AFFiRiS´ AFFITOME® technology, including candidate AD03. Based on the promising preliminary results of this programme, GSK exercised its option for the alternative vaccine candidates which triggered a EUR 2.5 million payment to AFFiRiS. An additional EUR 1 million payment became due simultaneously for the successful completion of tests of alternative vaccine formulations.

28 Feb 2011

UCSF collaborates with Zcube to develop new ways to deliver drugs

A pill filled with microscopic, drug-laden adhesive squares is at the center of an agreement between UCSF and Zcube srl, the research corporate venture arm of Italian pharmaceutical leader Zambon Co., SpA, to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.

28 Feb 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company's patent-pending MEDIHONEY® Gel Wound and Burn Dressing.

28 Feb 2011

FDA approves Matrix Labs generic Neurontin ANDA

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Gabapentin Capsules USP, 100 mg, 300 mg and 400 mg, the generic version of Pfizer's Neurontin® Capsules used to treat a painful complication of shingles.

28 Feb 2011

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Seattle Genetics, Inc. announced today that it has submitted a Biologics License Application to the U.S. Food and Drug Administration for the use of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma and relapsed or refractory systemic anaplastic large cell lymphoma.

28 Feb 2011

Janssen-Cilag, NovAlix enter research services agreement for chemistry to support drug discovery efforts

NovAlix today announces that it has entered into a multi-year research services agreement for chemistry with Janssen-Cilag, France, to support its drug discovery efforts.

28 Feb 2011

Researchers to examine thrombolysis for treatment of DVT in leg

Blood clots in the leg occur commonly. In one-half of the cases, the blood clot will break loose and travel through the bloodstream to the lungs - which may be life-threatening.

28 Feb 2011

Pharmaceutical News

Decision Resources: 52% of surveyed cardiologists identify furosemide as efficacious acute heart failure therapy

Excella achieves SafeBridge Potent Compound Safety Certification

Meda launches Medivir's cold sore treatment Xerese in the U.S.

Sweden's TLV confirms reimbursement for Qutenza patch for treatment of peripheral neuropathic pain

Santaris licenses miR-33 from MGH to treat cardiovascular disorders

Novavax announces agreement to license VLP vaccine technology to LGLS

HP announces innovative drug research application for its inkjet technology

AFFiRiS announces significant progress in collaboration with GSK for Alzheimer's vaccine development

Nile plans to develop novel therapeutics for ADHF

HHS awards two contracts to accelerate flu vaccine availability

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

AFFiRiS AG - Alzheimer's vaccines generate further cash flow

UCSF collaborates with Zcube to develop new ways to deliver drugs

TCD announces first patient treated in its TCD-717 Phase I trial

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

FDA grants 510(k) clearance for Derma Sciences MEDIHONEY Gel Wound and Burn Dressing

FDA approves Matrix Labs generic Neurontin ANDA

Seattle Genetics submits brentuximab vedotin BLA to FDA for treatment of ALCL, Hodgkin lymphoma

Janssen-Cilag, NovAlix enter research services agreement for chemistry to support drug discovery efforts

Researchers to examine thrombolysis for treatment of DVT in leg

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News